{"id":30612,"date":"2024-12-23T17:45:00","date_gmt":"2024-12-23T12:15:00","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=30612"},"modified":"2025-09-10T18:37:52","modified_gmt":"2025-09-10T13:07:52","slug":"promising-sle-drugs-in-pipeline","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/promising-sle-drugs-in-pipeline","title":{"rendered":"7 Late-Stage SLE Drugs Expected to Enter Therapeutic Domain"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a0ee0eb0c616\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a0ee0eb0c616\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/promising-sle-drugs-in-pipeline\/#7_Emerging_SLE_Drugs_in_Late-stage_Development\" >7 Emerging SLE Drugs in Late-stage Development<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/promising-sle-drugs-in-pipeline\/#Biogens_Litifilimab\" >Biogen\u2019s Litifilimab<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/promising-sle-drugs-in-pipeline\/#NovartisMorphoSys_Ianalumab\" >Novartis\/MorphoSys\u2019 Ianalumab<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/promising-sle-drugs-in-pipeline\/#Idorsia_PharmaceuticalsViatriss_Cenerimod\" >Idorsia Pharmaceuticals\/Viatris\u2019s Cenerimod<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/promising-sle-drugs-in-pipeline\/#UCBBiogens_Dapirolizumab_pegol\" >UCB\/Biogen\u2019s Dapirolizumab pegol&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/promising-sle-drugs-in-pipeline\/#AbbVies_RINVOQ\" >AbbVie\u2019s RINVOQ<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.delveinsight.com\/blog\/promising-sle-drugs-in-pipeline\/#Bristol-Myers_Squibbs_Deucravacitinib\" >Bristol-Myers Squibb\u2019s Deucravacitinib<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.delveinsight.com\/blog\/promising-sle-drugs-in-pipeline\/#Roches_Obinutuzumab\" >Roche\u2019s Obinutuzumab<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/www.delveinsight.com\/blog\/promising-sle-drugs-in-pipeline\/#SLE_Treatment_Space_What_Lies_Ahead\" >SLE Treatment Space: What Lies Ahead?<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>Systemic lupus erythematosus (SLE) is a chronic autoimmune condition that can affect multiple parts of the body. In 2023, it was estimated that around <strong>500,000<\/strong> individuals in the United States were living with SLE, as per DelveInsight analysis. The prevalence is significantly higher in females, who account for over <strong>90%<\/strong> of all cases. Among <a href=\"https:\/\/www.delveinsight.com\/report-store\/systemic-lupus-erythematosus-epidemiology-forecast\">treated SLE patients<\/a> in 2023, approximately <strong>40%<\/strong> experienced relapse or became refractory to first-line therapy. Currently, the biologics approved by the US FDA as adjunct SLE drugs for patients are <strong>BENLYSTA <\/strong>and <strong>SAPHNELO<\/strong>. In contrast, the use of rituximab<strong> <\/strong>for treating SLE is considered off-label.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-7-emerging-sle-drugs-in-late-stage-development\"><span class=\"ez-toc-section\" id=\"7_Emerging_SLE_Drugs_in_Late-stage_Development\"><\/span><strong>7 Emerging SLE Drugs in Late-stage Development<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>SLE pipeline possesses some drugs in late-stage developments to be approved in the near future. The <a href=\"https:\/\/www.delveinsight.com\/report-store\/systemic-lupus-erythematosus-pipeline-insight\">emerging SLE treatment landscape<\/a> holds a diverse range of therapeutic alternatives, including <strong>Litifilimab <\/strong>(Biogen), <strong>Ianalumab <\/strong>(Novartis), <strong>Cenerimod <\/strong>(Idorsia\/Viatris), <strong>Dapirolizumab pegol<\/strong> (UCB\/Biogen), <strong>Obinutuzumab <\/strong>(Roche), <strong>RINVOQ <\/strong>(AbbVie), <strong>Deucravacitinib <\/strong>(Bristol-Myers Squibb), and others in different lines of treatment. The expected launch of these therapies shall further create a positive impact on the market.<\/p>\n\n\n\n<p><em>Let\u2019s take a closer look at these emerging SLE drugs.<\/em><\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-biogen-s-litifilimab\"><span class=\"ez-toc-section\" id=\"Biogens_Litifilimab\"><\/span><strong>Biogen\u2019s Litifilimab<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>Litifilimab (BIIB059)<\/strong> is a humanized <strong>IgG1 monoclonal antibody<\/strong> developed by <strong>Biogen <\/strong>that targets blood dendritic cell antigen 2 (BDCA2). It is being studied for its potential to treat systemic lupus erythematosus and cutaneous lupus erythematosus (CLE), both chronic autoimmune diseases. This antibody binds specifically to BDCA2, a receptor found exclusively on plasmacytoid dendritic cells (pDCs), and blocks the production of type-I interferon (IFN-I) and other pro-inflammatory cytokines. This action is significant because pDCs are a major source of IFN-I in response to immune triggers, contributing to the inflammation observed in lupus. Currently, BIIB059 is in <a href=\"https:\/\/www.delveinsight.com\/report-store\/systemic-lupus-erythematosus-pipeline-insight\">Phase III clinical trials for SLE treatment<\/a>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-novartis-morphosys-ianalumab\"><span class=\"ez-toc-section\" id=\"NovartisMorphoSys_Ianalumab\"><\/span><strong>Novartis\/MorphoSys\u2019 Ianalumab<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>Ianalumab<\/strong>, a <strong>Novartis-developed antibody<\/strong>, targets the <strong>B-cell activating factor receptor (BAFF-R)<\/strong> to inhibit BAFF-R-mediated signaling and eliminate B cells via antibody-dependent cellular cytotoxicity. It is currently undergoing Phase III clinical trials for SLE, with the company expecting to submit it for approval by 2027, as highlighted in a recent presentation.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-idorsia-pharmaceuticals-viatris-s-cenerimod\"><span class=\"ez-toc-section\" id=\"Idorsia_PharmaceuticalsViatriss_Cenerimod\"><\/span><strong>Idorsia Pharmaceuticals\/Viatris\u2019s Cenerimod<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>Cenerimod <\/strong>is a highly selective modulator of the <strong>sphingosine-1-phosphate receptor 1 (S1P1)<\/strong>, administered as a once-daily oral tablet. Although the exact cause of SLE remains unclear, T and B lymphocytes are believed to be key immune cells involved in its development, with S1P1 receptors present on their surfaces. In February 2024, Idorsia Pharmaceuticals entered into a major global research and development partnership with Viatris for the advancement and commercialization of two Phase III candidates, selatogrel and cenerimod.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-ucb-biogen-s-dapirolizumab-pegol-nbsp\"><span class=\"ez-toc-section\" id=\"UCBBiogens_Dapirolizumab_pegol\"><\/span><strong>UCB\/Biogen\u2019s Dapirolizumab pegol&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>Dapirolizumab pegol<\/strong> is an innovative investigational treatment made up of a humanized, <strong>Fc-free antigen-binding (Fab\u2019)<\/strong> fragment attached to polyethylene glycol (PEG). It functions by inhibiting CD40L signaling, which has been shown to reduce B cell activation, limit autoantibody production, decrease type 1 interferon (IFN) secretion, and suppress the activation of T cells and antigen-presenting cells (APCs).<\/p>\n\n\n\n<p>In September 2024, UCB and Biogen announced that the <strong>Phase III PHOENYCS GO trial<\/strong> met its primary objective, demonstrating clinical improvements in <a href=\"https:\/\/www.delveinsight.com\/report-store\/systemic-lupus-erythematosus-market\">patients with moderate-to-severe systemic lupus erythematosus<\/a>. Additionally, key secondary endpoints, evaluating disease activity and flare-ups, also showed clinical benefits.<\/p>\n\n\n\n<p>Following the positive results from the PHOENYCS GO study, UCB and Biogen are initiating a second Phase III trial of dapirolizumab pegol in 2024, named <strong>PHOENYCS FLY<\/strong>. Participants from the PHOENYCS GO study will continue to be monitored in a long-term open-label extension.<\/p>\n\n\n\n<p>In November 2024, UCB and Biogen Inc. revealed comprehensive findings from the Phase III PHOENYCS GO study assessing dapirolizumab pegol. These results were presented during an oral, late-breaking session at <strong>ACR Convergence 2024<\/strong>, the American College of Rheumatology\u2019s annual meeting in Washington, DC.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"532\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/20104449\/Emerging-Systemic-Lupus-Erythematosus-Therapies-1024x532.png\" alt=\"Emerging-Systemic-Lupus-Erythematosus-Therapies\" class=\"wp-image-30618\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/20104449\/Emerging-Systemic-Lupus-Erythematosus-Therapies-1024x532.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/20104449\/Emerging-Systemic-Lupus-Erythematosus-Therapies-300x156.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/20104449\/Emerging-Systemic-Lupus-Erythematosus-Therapies-150x78.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/20104449\/Emerging-Systemic-Lupus-Erythematosus-Therapies-768x399.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/20104449\/Emerging-Systemic-Lupus-Erythematosus-Therapies-1536x798.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/20104449\/Emerging-Systemic-Lupus-Erythematosus-Therapies-2048x1064.png 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-abbvie-s-rinvoq\"><span class=\"ez-toc-section\" id=\"AbbVies_RINVOQ\"><\/span><strong>AbbVie\u2019s RINVOQ<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>As the patent of AbbVie\u2019s megablockbuster HUMIRA expired last year, the company has high hopes for their immunology successors RINVOQ and SKYRIZI. RINVOQ (upadacitinib) inhibits <strong>Janus kinase (JAK) enzymes<\/strong> within the JAK-STAT signaling pathway, which is involved in the release of pro-inflammatory cytokines. The FDA has authorized its use for treating eight autoimmune disorders: atopic dermatitis, ankylosing spondylitis, axial spondyloarthritis, Crohn\u2019s disease, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and polyarticular juvenile idiopathic arthritis.<\/p>\n\n\n\n<p>In June 2024, AbbVie launched RINVOQ in the US as both a tablet and oral solution for pediatric patients aged two years and older with polyarticular juvenile idiopathic arthritis and psoriatic arthritis who did not respond adequately or were intolerant to one or more tumor necrosis factor blockers. This marks RINVOQ\u2019s first pediatric indications, bringing its total approved indications for immune-mediated inflammatory diseases to eight. Currently RINVOQ is being evaluated in the phase III <a href=\"https:\/\/www.delveinsight.com\/report-store\/systemic-lupus-erythematosus-pipeline-insight\">trials for SLE treatment<\/a>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-bristol-myers-squibb-s-deucravacitinib\"><span class=\"ez-toc-section\" id=\"Bristol-Myers_Squibbs_Deucravacitinib\"><\/span><strong>Bristol-Myers Squibb\u2019s Deucravacitinib<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>SOTYKTU (deucravacitinib)<\/strong> is an oral, selective allosteric inhibitor of <strong>tyrosine kinase 2 (TYK2)<\/strong> with a distinct mechanism of action, representing a new class of small molecules. It is the first selective TYK2 inhibitor being tested in clinical trials for various immune-mediated diseases. Developed by Bristol Myers Squibb, Sotyktu targets TYK2 to block the signaling of interleukin (IL)-23, IL-12, and Type 1 interferons (IFN), which are key cytokines involved in the development of several immune-mediated diseases. By binding to the regulatory domain of TYK2, Sotyktu achieves high selectivity, leading to allosteric inhibition of TYK2 and its downstream effects. At therapeutic doses, it specifically inhibits TYK2 without affecting JAK1, JAK2, or JAK3. Currently, BMS is evaluating SOTYKTU in the late stages for SLE treatment.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-roche-s-obinutuzumab\"><span class=\"ez-toc-section\" id=\"Roches_Obinutuzumab\"><\/span><strong>Roche\u2019s Obinutuzumab<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p><strong>GAZYVA\/GAZYVARO (obinutuzumab, RG7159, GA101)<\/strong> is the first glycoengineered, type II, humanized monoclonal antibody targeting <strong>CD20<\/strong>. It operates differently from other anti-CD20 antibodies, such as MabThera\/Rituxan, and was specifically designed to target the CD20 protein on B cells with high affinity, binding to the cell surface in a type II configuration. GAZYVA has received approval in 100 countries for the treatment of various lymphoma types. In the United States, it is involved in a partnership between Genentech and Biogen. Currently, it is being evaluated in the phase III trials for SLE treatment.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-sle-treatment-space-what-lies-ahead\"><span class=\"ez-toc-section\" id=\"SLE_Treatment_Space_What_Lies_Ahead\"><\/span><strong>SLE Treatment Space: What Lies Ahead?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The treatment landscape for systemic lupus erythematosus (SLE) is undergoing significant transformation, driven by advances in understanding its pathophysiology and the development of targeted therapies. Historically, SLE management has focused on immunosuppressive agents like corticosteroids and antimalarials to control inflammation and prevent flare-ups.&nbsp;<\/p>\n\n\n\n<p>However, these therapies often come with side effects and limited efficacy in certain patient subsets. Recent breakthroughs in biologics, such as belimumab and voclosporin, have shown promising results, targeting specific immune pathways involved in SLE. Additionally, the emergence of targeted small molecules and the growing understanding of biomarkers are paving the way for personalized treatment approaches that aim to reduce disease activity while minimizing adverse effects.<\/p>\n\n\n\n<p>DelveInsight estimates that the <a href=\"https:\/\/www.delveinsight.com\/report-store\/systemic-lupus-erythematosus-market\">market size for SLE<\/a> is expected to grow from <strong>USD 3.2 billion<\/strong> in 2023 with a significant CAGR by 2034. This growth is mainly driven by ongoing clinical research and better diagnostic tools that might improve the prognosis of the disease.<\/p>\n\n\n\n<p>Looking ahead, the future of SLE treatment lies in the refinement of combination therapies, better patient stratification, and advancements in precision medicine. Researchers are focusing on developing therapies that not only target B cells and T cells but also modulate the complement system, cytokine pathways, and other key immune responses implicated in disease progression.&nbsp;<\/p>\n\n\n\n<p>The goal is to achieve sustained remission and improve long-term outcomes for SLE patients, especially for those with refractory disease. With ongoing clinical trials and the rapid expansion of new drug classes, there is optimism that the next decade will bring more effective and individualized treatment options, offering better disease control and an improved quality of life for those affected by this complex autoimmune disorder.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/systemic-lupus-erythematosus-market\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/20104415\/Systemic-Lupus-Erythematosus-Market-Outlook-1024x194.png\" alt=\"Systemic Lupus Erythematosus Market Outlook\" class=\"wp-image-30617\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/20104415\/Systemic-Lupus-Erythematosus-Market-Outlook-1024x194.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/20104415\/Systemic-Lupus-Erythematosus-Market-Outlook-300x57.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/20104415\/Systemic-Lupus-Erythematosus-Market-Outlook-150x28.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/20104415\/Systemic-Lupus-Erythematosus-Market-Outlook-768x145.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/20104415\/Systemic-Lupus-Erythematosus-Market-Outlook-1536x291.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/20104415\/Systemic-Lupus-Erythematosus-Market-Outlook.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<p><strong>FAQs<\/strong><\/p>\n\n\n\n<div class=\"schema-faq wp-block-yoast-faq-block\"><div class=\"schema-faq-section\" id=\"faq-question-1757509582585\"><strong class=\"schema-faq-question\"><strong>Why are late-stage SLE drugs generating so much anticipation?<\/strong><\/strong> <p class=\"schema-faq-answer\">Nearly <strong>40% of treated SLE patients relapse or become refractory<\/strong> to first-line therapy. Novel candidates like litifilimab, ianalumab, and deucravacitinib are designed to hit unique immune targets, potentially delivering efficacy in patient subsets left underserved by BENLYSTA and SAPHNELO.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1757509597006\"><strong class=\"schema-faq-question\"><strong>Which drugs could emerge as game-changers in the SLE landscape?<\/strong><\/strong> <p class=\"schema-faq-answer\">Biogen\u2019s <strong>litifilimab<\/strong> (targeting BDCA2 on plasmacytoid dendritic cells) and Novartis\u2019 <strong>ianalumab<\/strong> (blocking BAFF-R signaling) are strong contenders, while AbbVie\u2019s <strong>RINVOQ<\/strong> and BMS\u2019s <strong>deucravacitinib<\/strong> bring oral small-molecule convenience into a space dominated by injectables.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1757509597577\"><strong class=\"schema-faq-question\"><strong>How are strategic partnerships influencing the SLE competitive landscape?<\/strong><\/strong> <p class=\"schema-faq-answer\">The 2024 alliance between <strong>Idorsia and Viatris<\/strong> for cenerimod highlights how collaborations are accelerating late-stage development and commercialization, a trend likely to define competitive positioning in the SLE market.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1757509598569\"><strong class=\"schema-faq-question\"><strong>What makes dapirolizumab pegol a potential milestone therapy?<\/strong><\/strong> <p class=\"schema-faq-answer\">Positive Phase III results from the <strong>PHOENYCS GO trial<\/strong> showed improvements in disease activity and flare reduction, making it one of the most advanced candidates to challenge current standards and expand options for moderate-to-severe SLE.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1757509599128\"><strong class=\"schema-faq-question\"><strong>Could SLE treatment move toward precision medicine by 2034?<\/strong><\/strong> <p class=\"schema-faq-answer\">Yes. With biomarker-driven patient stratification, combination approaches, and therapies targeting B cells, T cells, and cytokine pathways, the next decade is expected to usher in more personalized regimens with the goal of sustained remission.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1757509642776\"><strong class=\"schema-faq-question\"><strong>How big is the SLE treatment market, and where is it headed?<\/strong><\/strong> <p class=\"schema-faq-answer\">The SLE market was valued at <strong>USD 3.2 billion in 2023<\/strong> and is projected to grow significantly by 2034, fueled by late-stage biologics and small molecules targeting specific immune pathways beyond traditional corticosteroids and immunosuppressants.<\/p> <\/div> <\/div>\n","protected":false},"excerpt":{"rendered":"<p>Systemic lupus erythematosus (SLE) is a chronic autoimmune condition that can affect multiple parts of the body. In 2023, it was estimated that around 500,000 individuals in the United States were living with SLE, as per DelveInsight analysis. The prevalence is significantly higher in females, who account for over 90% of all cases. Among treated [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":30614,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[22393,22392,721,1248,1247,1246,1244,1242,1245,1243],"industry":[17225],"therapeutic_areas":[17227],"class_list":["post-30612","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-sle-drugs","tag-sle-treatment","tag-systemic-lupus-erythematosus","tag-systemic-lupus-erythematosus-active-companies","tag-systemic-lupus-erythematosus-clinical-trial","tag-systemic-lupus-erythematosus-drug-launch","tag-systemic-lupus-erythematosus-drugs","tag-systemic-lupus-erythematosus-market","tag-systemic-lupus-erythematosus-market-size","tag-systemic-lupus-erythematosus-pipeline","industry-pharmaceutical","therapeutic_areas-immunological-and-autoimmune-disorders"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>7 Promising Late-Stage SLE Drugs to Watch Out<\/title>\n<meta name=\"description\" content=\"SLE pipeline possesses some drugs in late-stage to be approved in near future. Expected launch of these therapies further propel market.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/promising-sle-drugs-in-pipeline\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"7 Promising Late-Stage SLE Drugs to Watch Out\" \/>\n<meta property=\"og:description\" content=\"SLE pipeline possesses some drugs in late-stage to be approved in near future. Expected launch of these therapies further propel market.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/promising-sle-drugs-in-pipeline\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-23T12:15:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-10T13:07:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/20104242\/promising-sle-drugs-in-pipeline.png\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"7 Promising Late-Stage SLE Drugs to Watch Out","description":"SLE pipeline possesses some drugs in late-stage to be approved in near future. Expected launch of these therapies further propel market.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/promising-sle-drugs-in-pipeline","og_locale":"en_US","og_type":"article","og_title":"7 Promising Late-Stage SLE Drugs to Watch Out","og_description":"SLE pipeline possesses some drugs in late-stage to be approved in near future. Expected launch of these therapies further propel market.","og_url":"https:\/\/www.delveinsight.com\/blog\/promising-sle-drugs-in-pipeline","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2024-12-23T12:15:00+00:00","article_modified_time":"2025-09-10T13:07:52+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/20104242\/promising-sle-drugs-in-pipeline.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["WebPage","FAQPage"],"@id":"https:\/\/www.delveinsight.com\/blog\/promising-sle-drugs-in-pipeline","url":"https:\/\/www.delveinsight.com\/blog\/promising-sle-drugs-in-pipeline","name":"7 Promising Late-Stage SLE Drugs to Watch Out","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/promising-sle-drugs-in-pipeline#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/promising-sle-drugs-in-pipeline#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/20104242\/promising-sle-drugs-in-pipeline.png","datePublished":"2024-12-23T12:15:00+00:00","dateModified":"2025-09-10T13:07:52+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"SLE pipeline possesses some drugs in late-stage to be approved in near future. Expected launch of these therapies further propel market.","mainEntity":[{"@id":"https:\/\/www.delveinsight.com\/blog\/promising-sle-drugs-in-pipeline#faq-question-1757509582585"},{"@id":"https:\/\/www.delveinsight.com\/blog\/promising-sle-drugs-in-pipeline#faq-question-1757509597006"},{"@id":"https:\/\/www.delveinsight.com\/blog\/promising-sle-drugs-in-pipeline#faq-question-1757509597577"},{"@id":"https:\/\/www.delveinsight.com\/blog\/promising-sle-drugs-in-pipeline#faq-question-1757509598569"},{"@id":"https:\/\/www.delveinsight.com\/blog\/promising-sle-drugs-in-pipeline#faq-question-1757509599128"},{"@id":"https:\/\/www.delveinsight.com\/blog\/promising-sle-drugs-in-pipeline#faq-question-1757509642776"}],"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/promising-sle-drugs-in-pipeline"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/promising-sle-drugs-in-pipeline#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/20104242\/promising-sle-drugs-in-pipeline.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/20104242\/promising-sle-drugs-in-pipeline.png","width":466,"height":284,"caption":"promising-sle-drugs-in-pipeline"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/promising-sle-drugs-in-pipeline#faq-question-1757509582585","position":1,"url":"https:\/\/www.delveinsight.com\/blog\/promising-sle-drugs-in-pipeline#faq-question-1757509582585","name":"Why are late-stage SLE drugs generating so much anticipation?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Nearly <strong>40% of treated SLE patients relapse or become refractory<\/strong> to first-line therapy. Novel candidates like litifilimab, ianalumab, and deucravacitinib are designed to hit unique immune targets, potentially delivering efficacy in patient subsets left underserved by BENLYSTA and SAPHNELO.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/promising-sle-drugs-in-pipeline#faq-question-1757509597006","position":2,"url":"https:\/\/www.delveinsight.com\/blog\/promising-sle-drugs-in-pipeline#faq-question-1757509597006","name":"Which drugs could emerge as game-changers in the SLE landscape?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Biogen\u2019s <strong>litifilimab<\/strong> (targeting BDCA2 on plasmacytoid dendritic cells) and Novartis\u2019 <strong>ianalumab<\/strong> (blocking BAFF-R signaling) are strong contenders, while AbbVie\u2019s <strong>RINVOQ<\/strong> and BMS\u2019s <strong>deucravacitinib<\/strong> bring oral small-molecule convenience into a space dominated by injectables.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/promising-sle-drugs-in-pipeline#faq-question-1757509597577","position":3,"url":"https:\/\/www.delveinsight.com\/blog\/promising-sle-drugs-in-pipeline#faq-question-1757509597577","name":"How are strategic partnerships influencing the SLE competitive landscape?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"The 2024 alliance between <strong>Idorsia and Viatris<\/strong> for cenerimod highlights how collaborations are accelerating late-stage development and commercialization, a trend likely to define competitive positioning in the SLE market.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/promising-sle-drugs-in-pipeline#faq-question-1757509598569","position":4,"url":"https:\/\/www.delveinsight.com\/blog\/promising-sle-drugs-in-pipeline#faq-question-1757509598569","name":"What makes dapirolizumab pegol a potential milestone therapy?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Positive Phase III results from the <strong>PHOENYCS GO trial<\/strong> showed improvements in disease activity and flare reduction, making it one of the most advanced candidates to challenge current standards and expand options for moderate-to-severe SLE.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/promising-sle-drugs-in-pipeline#faq-question-1757509599128","position":5,"url":"https:\/\/www.delveinsight.com\/blog\/promising-sle-drugs-in-pipeline#faq-question-1757509599128","name":"Could SLE treatment move toward precision medicine by 2034?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Yes. With biomarker-driven patient stratification, combination approaches, and therapies targeting B cells, T cells, and cytokine pathways, the next decade is expected to usher in more personalized regimens with the goal of sustained remission.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/promising-sle-drugs-in-pipeline#faq-question-1757509642776","position":6,"url":"https:\/\/www.delveinsight.com\/blog\/promising-sle-drugs-in-pipeline#faq-question-1757509642776","name":"How big is the SLE treatment market, and where is it headed?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"The SLE market was valued at <strong>USD 3.2 billion in 2023<\/strong> and is projected to grow significantly by 2034, fueled by late-stage biologics and small molecules targeting specific immune pathways beyond traditional corticosteroids and immunosuppressants.","inLanguage":"en-US"},"inLanguage":"en-US"}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/12\/20104242\/promising-sle-drugs-in-pipeline-300x183.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">SLE Drugs<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">SLE Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Systemic Lupus Erythematosus<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Systemic Lupus Erythematosus active companies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Systemic Lupus Erythematosus clinical trial<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Systemic Lupus Erythematosus drug launch<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Systemic Lupus Erythematosus drugs<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Systemic Lupus Erythematosus market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Systemic Lupus Erythematosus market size<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Systemic Lupus Erythematosus pipeline<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">SLE Drugs<\/span>","<span class=\"advgb-post-tax-term\">SLE Treatment<\/span>","<span class=\"advgb-post-tax-term\">Systemic Lupus Erythematosus<\/span>","<span class=\"advgb-post-tax-term\">Systemic Lupus Erythematosus active companies<\/span>","<span class=\"advgb-post-tax-term\">Systemic Lupus Erythematosus clinical trial<\/span>","<span class=\"advgb-post-tax-term\">Systemic Lupus Erythematosus drug launch<\/span>","<span class=\"advgb-post-tax-term\">Systemic Lupus Erythematosus drugs<\/span>","<span class=\"advgb-post-tax-term\">Systemic Lupus Erythematosus market<\/span>","<span class=\"advgb-post-tax-term\">Systemic Lupus Erythematosus market size<\/span>","<span class=\"advgb-post-tax-term\">Systemic Lupus Erythematosus pipeline<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 1 year ago","modified":"Updated 8 months ago"},"absolute_dates":{"created":"Posted on Dec 23, 2024","modified":"Updated on Sep 10, 2025"},"absolute_dates_time":{"created":"Posted on Dec 23, 2024 5:45 pm","modified":"Updated on Sep 10, 2025 6:37 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30612","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=30612"}],"version-history":[{"count":3,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30612\/revisions"}],"predecessor-version":[{"id":33359,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/30612\/revisions\/33359"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/30614"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=30612"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=30612"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=30612"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=30612"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=30612"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}